AVENTIS Form SC TO-T/A July 29, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE TO

(Amendment No. 7)

Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934

AVENTIS

(Name of Subject Company (Issuer))

 $\begin{array}{c} {\tt SANOFI-SYNTHELABO} \\ {\tt (Name of Filing Person (Offeror))} \end{array}$

Ordinary Shares, nominal value (euro)3.82 per Ordinary Share (Title of Class of Securities)

ISIN No. FR0000130460 (CUSIP Number of Class of Securities)

American Depositary Shares
(each representing one Ordinary Share)
(Title of Class of Securities)

053561106 (CUSIP Number of Class of Securities)

John Spinnato
General Counsel, Vice President and Secretary
Sanofi-Synthelabo Inc.
90 Park Avenue
New York, NY 10016
Tel: (212) 551-4000

(Name, address and telephone number of person authorized to receive notices and communications on behalf of the filing person)

Copies to:

Laurent Cohen-Tanugi David A. Katz, Esq
Senior Vice President and General Counsel
Sanofi-Synthelabo 51 West 52nd Street
174 avenue de France
75013 Paris, France
Tel: + 33 1 53 77 40 00

|_| Check the box if the filing relates solely to preliminary
communications made before commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which this statement relates:

|X| Third party tender offer subject to Rule 14d-1

- 1_1 Issuer tender offer subject to Rule 13e-4
- 1_1 Going private transaction subject to Rule 13e-3
- Amendment to Schedule 13D under Rule 13d-2

Check the following box if the filing is a final amendment reporting the results of the tender offer: |_|

Sanofi-Synthelabo, a French societe anonyme, amends and supplements its Tender Offer Statement on Schedule TO, as amended (the "Schedule TO"), filed initially with the United States Securities and Exchange Commission on April 12, 2004 in connection with Sanofi-Synthelabo's offer to acquire (1) all ordinary shares, nominal value (euro)3.82 per share, of Aventis, a French societe anonyme, that are held by holders who are located in the United States and (2) all American Depositary Shares of Aventis (each an "Aventis ADS", and each Aventis ADS representing one Aventis ordinary share), held by holders wherever located, pursuant to the terms and subject to the conditions set forth in the definitive Prospectus, dated April 9, 2004, and the definitive Prospectus Supplement, dated May 27, 2004 (collectively, the "Prospectus"), and the related amended ADS Letter of Transmittal and amended Form of Acceptance (collectively with the Prospectus, and as amended and supplemented hereby, the "Revised U.S. Offer"). This amendment constitutes Amendment No. 7 to the Schedule TO. Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Schedule TO.

ITEM 12. EXHIBIT

ITEM 1

TTS	
2 IS AMENDED AND SU	PPLEMENTED TO INCLUDE THE FOLLOWING EXHIBITS:
(a) (5) (xxv)	Press Release, dated June 25, 2004, announcing that Sanofi-Synthelabo and Pfizer have concluded an agreement on the divestment of Campto(R) (Irinotecan), conditional upon completion of Sanofi-Synthelabo's offer for Aventis (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on June 25, 2004)
(a) (5) (xxvi)	Press Release, dated July 15, 2004, announcing that the U.S. Federal Trade Commission's Bureau of Competition and Economics has completed its review of Sanofi-Synthelabo's proposed acquisition of Aventis (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on July 15, 2004)
(a) (5) (xxvii)	Press Release, dated July 21, 2004, announcing Sanofi-Synthelabo's consolidated sales for the first half of 2004 (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on July 21, 2004)
(a)(5)(xxviii)	Press Release, dated July 29, 2004,

announcing that the U.S. Federal Trade Commission has accepted Sanofi-Synthelabo's consent decree (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on July 29, 2004)

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Schedule TO is true, complete and correct.

SANOFI-SYNTHELABO

July 29, 2004 By: /S/: JEAN-CLAUDE LEROY

Name: Jean-Claude Leroy

Title: Senior Vice President -- Strategy

EXHIBIT INDEX

EXHIBIT NUMBER	DESCRIPTION
(a)(1)(i)	ADS Letter of Transmittal (Aventis ADSs)*
(a)(1)(ii)	Notice of Guaranteed Delivery (Aventis ADSs)*
(a)(1)(iii)	Letter to Brokers, Dealers, Commercial Banks, Trust Companies and other Nominees (Aventis ADSs)*
(a)(1)(iv)	Letter to Clients from Brokers, Dealers, Commercial Banks, Trust Companies and other Nominees (Aventis ADSs)*
(a)(1)(v)	Guidelines for Certification of Taxpayer Indemnification Number on Substitute Form W-9* $$
(a)(1)(vi)	Form of Acceptance for Aventis Ordinary Shares*
(a)(1)(vii)	Technical Notice to French Financial Intermediaries and U.S. Custodians (Aventis ordinary shares)*
(a)(1)(viii)	Letter to Clients from Brokers, Dealers, Commercial Banks, Trust Companies and other Nominees (Aventis ordinary shares)*

(a)(1)(ix)	ADS Letter of Transmittal (Aventis ADSs) (Revised U.S. Offer)****
(a) (1) (x)	Notice of Guaranteed Delivery (Aventis ADSs) (Revised U.S. Offer) ****
(a)(1)(xi)	Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees (Aventis ADSs) (Revised U.S. Offer) ****
(a)(1)(xii)	Letter to Clients from Brokers, Dealers, Commercial Banks, Trust Companies and other Nominees (Aventis ADSs) (Revised U.S. Offer) ****
(a)(1)(xiii)	Form of Acceptance for Aventis Ordinary Shares (Revised U.S. Offer) ****
(a)(1)(xiv)	Technical Notice to French Financial Intermediaries and U.S. Custodians (Aventis ordinary shares) (Revised U.S. Offer) ****
(a) (1) (xv)	Letter to Clients from Brokers, Dealers, Commercial Banks, Trust Companies and other Nominees (Aventis ordinary shares) (Revised U.S. Offer) ****
(a) (2)	None
(a) (3)	Not applicable
(a) (4)	Prospectus, dated April 9, 2004 (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 424(b)(5) on April 12, 2004 (File no: 333-112314))
(a)(4)(ii)	Preliminary Prospectus Supplement, dated May 4, 2004 (incorporated herein by reference to Post-Effective Amendment No. 1 to Sanofi-Synthelabo's Registration Statement on Form F-4, dated May 5, 2004 (File no: 333-112314))
(a)(4)(iii)	Definitive Prospectus Supplement, dated May 27, 2004 (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 424(b)(5) on May 28, 2004 (File no: 333-112314))
(a)(5)(i)	Press release announcing the offer for Aventis, dated January 26, 2004 (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on January 26, 2004)
(a)(5)(ii)	Press release announcing commencement of U.S. offer, dated April 12, 2004 (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on April 12, 2004)
(a)(5)(iii)	Text of newspaper advertisement dated April 12, 2004 and published in the Wall Street Journal*
(a)(5)(iv)	Press release announcing the entry into an agreement with GlaxoSmithKline regarding the divestiture of Arixtra(R), Fraxiparine(R) and related assets, dated April 13, 2004 (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on April 13, 2004)
(a) (5) (v)	Press release announcing the decision of Board of Directors of

Sanofi-Synthelabo to distribute an interim dividend, dated April 15, 2004 (incorporated herein by reference to the filing made by $\,$

EXHIBIT NUMBER	DESCRIPTION		
	Sanofi-Synthelabo pursuant to Rule 425(a) on April 15, 2004)		
(a)(5)(vi)	Complaint of Aventis, dated April 19, 2004, filed in the United States District Court for the District of New Jersey**		
(a)(5)(vii)	Press release announcing improved friendly offer, dated April 26, 2004 (incorporated herein by reference to Sanofi-Synthelabo's Form 6-K furnished to the SEC on April 26, 2004)		
(a)(5)(viii)	Presentation given by Mr. Jean-Francois Dehecq in Paris, France at an Information Meeting announcing the improved friendly offer (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on April 26, 2004)		
(a)(5)(ix)	Press release announcing the European Commission's approval of the proposed acquisition of Aventis by Sanofi-Synthelabo, dated April 27, 2004 (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on April 27, 2004)		
(a) (5) (x)	Press release announcing the postponement of the general meeting of Sanofi-Synthelabo shareholders, dated May 4, 2004 (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on May 4, 2004)		
(a)(5)(xi)	Press release announcing issuance of request for additional information by U.S. Federal Trade Commission, dated May 5, 2004 (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on May 5, 2004)		
(a)(5)(xii)	Press release announcing rescheduling of general meeting of Sanofi-Synthelabo shareholders for June 23, 2003, dated May 14, 2004 (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on May 14, 2004)		
(a)(5)(xiii)	Press release announcing, among other things, nominees for election as directors of Sanofi-Synthelabo, dated May 26, 2004 (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on May 26, 2004)		
(a)(5)(xiv)	Press release announcing extension of U.S. offer to June 30, 2004, dated May 26, 2004, (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on May 26, 2004)		
(a) (5) (xv)	Text of newspaper advertisement dated May 28, 2004 and published in the WALL STREET JOURNAL****		
(a)(5)(xvi)	Press release confirming extension of U.S. offer until June 30, 2004, dated June 1, 2004 (incorporated herein by reference		

	to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on June 1, 2004)
(a)(5)(xvii)	Press release regarding new indications for Arixtra(R), dated June 4, 2004 (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on June 4, 2004)
(a)(5)(xviii)	Employee communication regarding the offers, published in "La Lettre Bleue No. 2", dated June 7, 2004 (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on June 7, 2004)
(a)(5)(xix)	Press release announcing adjusted offer consideration after confirmation of Aventis dividend, dated June 14, 2004 (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on June 14, 2004)
(a) (5) (xx)	Press Release, dated June 21, 2004, announcing the draft structure of SANOFI-AVENTIS Management Committee (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on June 22, 2004)
(a)(5)(xxi)	Press Release, dated June 22, 2004, announcing the AMF's decision to postpone the closing date of Sanofi-Synthelabo's Offer for Aventis until July 30, 2004 (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on June 22, 2004)
(a)(5)(xxii)	Press Release, dated June 23, 2004, confirming the extension of the U.S. Offer, the French Offer and the German Offer (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on June 23, 2004)
EXHIBIT NUMBER	DESCRIPTION
(a)(5)(xxiii)	Presentation given by Mr. Jean-Francois Dehecq and other Sanofi-Synthelabo executives in Paris, France at Annual General Meeting of Sanofi-Synthelabo shareholders on June 23, 2004 (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on June 23, 2004)
(a)(5)(xxiv)	Press Release, dated June 24, 2004, announcing the results of Annual General Meeting of Sanofi-Synthelabo shareholders (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on June 24, 2004)
(a) (5) (xxv)	Press Release, dated June 25, 2004, announcing that Sanofi-Synthelabo and Pfizer have concluded an agreement on the divestment of Campto(R) (Irinotecan), conditional upon completion of Sanofi-Synthelabo's offer for Aventis (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on June 25, 2004)
(a)(5)(xxvi)	Press Release, dated July 15, 2004, announcing that the U.S. Federal Trade Commission's Bureau of Competition and Economics has completed its review of Sanofi-Synthelabo's proposed

acquisition of Aventis (incorporated herein by reference to
the filing made by Sanofi-Synthelabo pursuant to Rule 425(a)
on July 15, 2004)

(a)(5)(xxvii)	Press Release, dated July 21, 2004, announcing Sanofi-Synthelabo's consolidated sales for the first half of 2004 (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on July 21, 2004)
(a)(5)(xxviii)	Press Release, dated July 29, 2004, announcing that the U.S. Federal Trade Commission has accepted Sanofi-Synthelabo's consent decree (incorporated herein by reference to the filing made by Sanofi-Synthelabo pursuant to Rule 425(a) on July 29, 2004)
(b) (1)	Credit Facility Agreement, dated 25 January 2004 (incorporated herein by reference to Exhibit 10.4 to the Registration Statement on Form F-4 filed by Sanofi-Synthelabo (File No. 333-112314))
(b) (2)	Credit Facility Agreement, dated 26 April 2004 (incorporated herein by reference to Exhibit 10.5 of the Post-Effective Amendment No. 1 to Sanofi-Synthelabo's Registration Statement on Form F-4, dated May 5, 2004 (File no: 333-112314))
(d) (1)	Agreement, dated April 25, 2004, between Sanofi-Synthelabo and Aventis***
(d) (2)	Letter from Mr. Jean-Francois Dehecq to Mr. Igor Landau confirming certain severance and other employment-related benefits of Mr. Landau***
(d) (3)	Amendment Agreement, dated May 19, 2004, amending Schedule 1 to the Agreement, dated April 25, 2004, between Aventis and Sanofi-Synthelabo (incorporated herein by reference to Exhibit 99.1 to Sanofi-Synthelabo's Form 6-K, dated May [21], 2004 (File No. 001-31368))
(g)	None
(h) (1)	Opinion of Wachtell, Lipton, Rosen & Katz regarding certain United States federal income tax matters (incorporated herein by reference to Exhibit 8.1 to the Registration Statement on Form F-4 filed by Sanofi-Synthelabo (File No. 333-112314))
(h) (2)	Opinion of Linklaters regarding certain French tax matters (incorporated herein by reference to Exhibit 8.2 to the Registration Statement on Form F-4 filed by Sanofi-Synthelabo (File No. 333-112314))

^{*} Previously filed on Schedule TO dated April 12, 2004.

^{**} Previously filed on Amendment No. 1 to the Schedule TO dated April 20, 2004.

^{***} Previously filed on Amendment No. 2 to the Schedule TO dated April 26, 2004.

^{****}Previously filed on Amendment No. 4 to the Schedule TO dated May 28, 2004.

Assets

Investments, at fair value:

Shares of registered investment companies:

Mutual funds \$18,501,130 \$24,378,959 AZZ incorporated common stock 404,733 750,150 Money market fund 3,611,292 1,928,246 Participant loans 916,326 842,634 Total investments 23,433,481 27,899,989 Receivables:

Employer contributions 6,291,189 3,937,121 Participant contributions 106,185 97,329 Total receivables 6,397,374 4,034,450 Total assets 29,830,855 31,934,439 Liabilities

Excess contributions payable 78,805 - Net Assets Available for Benefits \$29,752,050 \$31,934,439

AZZ incorporated Employee Benefit Plan & Trust

Statements of Changes in Net Assets Available for Benefits

	Years Ended			
	February 28,		Feb	oruary 29,
	2009			2008
Additions to Net Assets				
Investment income (loss):				
Interest and dividend income	\$	923,630	\$	2,215,383
Net realized and unrealized losses		(10,730,820)		(1,719,984)
Total investment income (loss)		(9,807,190)		495,399
Contributions:				
Employer		7,605,401		4,872,141
Participants		2,864,065		2,539,697
Rollovers		241,435		110,308
Total contributions		10,710,901		7,522,146
Total additions		903,711		8,017,545
Deductions from Net Assets				
Benefits paid to participants		3,086,100		4,264,262
Net increase (decrease) in net assets available for				
benefits		(2,182,389)		3,753,283
Net assets available for benefits at beginning of year		31,934,439		28,181,156
Net assets available for benefits at end of year	\$	29,752,050	\$	31,934,439

AZZ incorporated Employee Benefit Plan & Trust

Notes to Financial Statements

February 28, 2009 and February 29, 2008

A. Description of the Plan

The following description of the AZZ incorporated Employee Benefit Plan & Trust (the "Plan") provides only general information. The Plan is sponsored by AZZ incorporated (the "Company"). Participants should refer to the Plan Agreement or Summary Plan Description for a more complete description of the Plan's provisions.

General

The Plan is a defined contribution plan covering substantially all full-time employees of the Company and its affiliates who have completed ninety days of service and attained 18 years of age. Eligibility for profit sharing begins after one year of service. Entry dates into the Plan are no later than the earlier of (a) six months after such eligibility requirements are met, or (b) the first day of the first Plan year after such requirements are met.

The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 ("ERISA").

The Company has adopted the MFS Retirement Services, Inc. ("MFS") Non-Standardized 401(k) Profit Sharing Plan and Trust and appointed MFS Heritage Trust Company as the trustee of the trust established under the Plan.

Effective February 1, 2007, MFS changed its name to Sun Life Retirement Services (U.S.), Inc. ("Sun Life"). Effective March 4, 2008, Sun Life Retirement Services (U.S.), Inc. changed its name to The Hartford Financial Services Group, Inc. ("The Hartford").

Contributions

Participants may elect to contribute from 1% to 50% of their eligible compensation, subject to Internal Revenue Code ("Code") limitations. The Company provides discretionary matching contributions equal to a percentage of participant contributions as determined annually by the Company's Board of Directors. Additionally, the Company may contribute discretionary profit sharing amounts to the Plan as determined each year by the Company's Board of Directors. To be eligible to receive matching contributions and profit sharing contributions, participants must be actively employed on the last day of the Plan year and must have completed 1,000 hours of service.

Participants may elect to commence voluntary contributions or modify the amount of voluntary contributions made on the first day of each quarter within the Plan year.

Participants who are eligible to make salary deferral contributions under the Plan and who have attained age 50 before the close of the Plan year may make catch-up contributions in accordance with, and subject to the limitations imposed by the Code.

AZZ incorporated Employee Benefit Plan & Trust

Notes to Financial Statements (continued)

A. Description of the Plan – continued

Participant Accounts

A separate account is maintained for each participant and is credited with participant contributions, Company contributions, and actual earnings thereon as well as forfeitures of terminated participants' non-vested accounts.

Forfeited Accounts

Forfeited balances of terminated participants' non-vested accounts are reallocated among the remaining participants in the proportion that each participant's compensation for the year bears to the total compensation of all participants for the year.

Investment Options

Unless specifically electing not to defer, all employees are automatically enrolled in the Plan in accordance with the terms and provisions of a Safe Harbor Amendment. Participants may direct contributions to their account in a variety of investment options, which vary in degree of risk, with the exception of AZZ incorporated common stock for which participants may only hold or sell existing shares. Participants may change their investment options at any time. Investments are held by The Hartford, the record keeper, funding agent, and a party-in-interest. Under a trust agreement with the Company, MFS Heritage Trust Company is a directed trustee.

Vesting

Participant contributions to the Plan plus actual earnings or losses thereon are fully vested at all times. The participant's share of matching contributions and profit sharing contributions and earnings and losses thereon which were contributed to the Plan prior to March 1, 2008 vest in accordance with the following schedule:

Years of	Vesting		
Service	Percentage		
	_		
Less than 1			
year	0	%	
1 year	20	%	
2 years	40	%	
3 years	60	%	
4 years	80	%	
5 years	100	%	

AZZ incorporated Employee Benefit Plan & Trust

Notes to Financial Statements (continued)

A. Description of the Plan – continued

Effective March 1, 2008, the participant's share of Qualified Automatic Contribution Agreement ("QACA") matching contributions and earnings and losses thereon vest in accordance with the Safe Harbor provisions and the following schedule:

Years of	Vesting	
Service	Percentage	•
Less than 2		
years	0	%
2 years	100	%

Profit sharing contributions continue to vest over the five year vesting schedule.

Participants will vest 100% upon attainment of age 65, or in the event of death or disability while employed by the Company.

Loans

Participants may borrow from their account a minimum of \$1,000 up to a maximum equal to the lesser of \$50,000 or 50% of their vested account balance. Loan terms range from one to five years. The loans are secured by the balance in the participant's account and bear interest at prime. Interest rates for 2009, ranged from 3.25% to 9.25%. Principal and interest are paid ratably through payroll deductions.

Participant Withdrawals

On termination of service, if a participant's vested benefits are less than \$5,000, the benefit is payable in a lump sum. If the vested benefit is greater than \$5,000, the participant may elect to receive either a lump-sum amount or annual installments over a period not to exceed the life expectancy of the participant and the participant's beneficiary. Prior to termination of service, a participant may elect to receive all, subject to certain restrictions, or any portion of their accrued benefit if the participant has participated in the Plan at least five years and is 100% vested.

B. Summary of Significant Accounting Policies

The financial statements of the Plan are presented on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.

AZZ incorporated Employee Benefit Plan & Trust

Notes to Financial Statements (continued)

B. Summary of Significant Accounting Policies – continued

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Accordingly, actual results may differ from these estimates.

Investment Valuation

The investments of the Plan are stated at fair value as of the end of the Plan year. In September 2006, the Financial Accounting Standards Board ("FASB") issued Statement of Financial Accounting Standards ("SFAS") 157, "Fair Value Measurements," which is effective for fiscal years beginning after November 15, 2007, with early adoption permitted. SFAS 157 defines fair value, establishes a framework for measuring fair value, and expands disclosures about assets and liabilities measured at fair value. The Plan adopted SFAS 157 effective March 1, 2008, which did not have material impact on the financial statements of the Plan. For information related to the Plan's valuation methodologies under SFAS 157, see Note D of these financial statements.

Purchases and sales of securities are recorded on the trade dates. Gains or losses on sales of securities are calculated using the average cost of the securities sold. Interest income is recorded on the accrual basis.

All investments and uninvested cash were held by The Hartford under a trust agreement. The Plan's investments are generally subject to market or credit risks customarily associated with debt and equity investments.

Contributions

Participant and employer contributions are accrued in the period in which they are deducted in accordance with salary deferral agreements and as they become obligations of the Company, as determined by the Plan's administrator.

Payment of Benefits

Benefits are recorded when paid.

Plan Expenses

Employees of the Company perform certain administrative functions with no compensation from the Plan. The Company or the Plan pays administrative expenses of the Plan. Administrative expenses paid by the Plan are properly reflected in the accompanying statements of changes in net assets available for benefits. There were no administrative expenses paid by the Plan in the 2009 or 2008 Plan years.

AZZ incorporated Employee Benefit Plan & Trust

Notes to Financial Statements (continued)

C. Investments

At February 28, 2009 and February 29, 2008, individual investments that represent 5% or more of the fair value of net assets available for benefits are as follows:

	2009
MFS Total Return Fund A	\$ 4,336,966
MFS Bond Fund A	4,214,734
MFS Money Market Fund	3,611,292
American Funds Growth Fund of America R4	3,299,694
MFS Value Fund A	2,755,489
MFS Global Equity Fund A	2,605,208
	2008
MFS Total Return Fund A	\$ 5,076,117
American Funds Growth Fund of America R4	4,778,143
MFS Value Fund A	4,441,670
MFS Bond Fund A	4,381,390
MFS Global Equity Fund A	4,068,120
MFS Money Market Fund	1,928,246

During the years ended February 28, 2009 and February 29, 2008, net realized and unrealized gains were comprised of the following:

	200	09	2008	
Mutual funds	\$	(10,438,217)	\$ (2,145,296)	
AZZ incorporated common stock		(292,603)	425,312	
Net realized and unrealized losses	\$	(10,730,820)	\$ (1,719,984)	

AZZ incorporated Employee Benefit Plan & Trust

Notes to Financial Statements (continued)

D. Fair Value Measurements

SFAS No. 157 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date and establishes a three-tier hierarchy that is used to identify assets and liabilities measured at fair value. The hierarchy focuses on the inputs used to measure fair value and requires that the lowest level input be used. The three levels defined in SFAS No. 157 are as follows:

- -Level 1: Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities as of the reporting date.
- -Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
 - Level 3: Unobservable inputs that are not corroborated by market data.

SFAS No. 157 requires a description of the methodologies used to measure the fair value of assets and liabilities. These methodologies were consistently applied to all assets carried as of February 28, 2009. The methodology used to measure each major category of assets and liabilities is as follows:

- -Mutual funds: Valued based on quoted market prices of the underlying assets provided by the trustee and are classified within Level 1 of the valuation hierarchy.
- -Common stock: Valued at the closing price reported on the active market on which the individual securities are traded and classified within Level 1 of the valuation hierarchy.
- -Money market fund: Valued based on the short-term cash component as of the measurement date and classified within Level 1 of the valuation hierarchy.
- -Participant loans: Valued at the outstanding principal balance, which approximates fair value and are classified within Level 2 of the valuation hierarchy.

AZZ incorporated Employee Benefit Plan & Trust

Notes to Financial Statements (continued)

D. Fair Value Measurements - continued

				ir Value Meass uoted Prices in Active	ırem	ents at Februa	ary 28,	2009 Using	
	Total Carrying Value as of February 28, 2009		Markets for Identical Assets (Level 1)		Significant Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)	
Mutual funds	\$	18,501,130	\$	18,501,130	\$	-	\$	-	
Common stock		404,733		404,733					
Money market fund		3,611,292		3,611,292					
Participant loans		916,326		_		916,326		_	
Total investment at fair value	\$	23,433,481	\$	22,517,155	\$	916,326	\$	-	

E. Forfeited Accounts

At February 28, 2009 and February 29, 2008, net assets available for benefits include approximately \$231,000 and \$157,000, respectively, of unallocated forfeitures. Unallocated forfeiture amounts will be appropriately allocated during the 2010 Plan year.

F. Excess Contributions Payable

The Code attempts to ensure that employees at all levels of income share the tax advantages of the Plan proportionally. A non-discrimination test is required by the Code to determine a contribution level that makes all participant contributions, as a percentage of compensation, fall within prescribed limits. The amounts accrued as an excess contributions payable to participants, represent contributions exceeding the allowed limits and will be refunded to employees subsequent to the end of each Plan year.

G. Plan Termination

Although it has not expressed any intent to do so, the Company has the right under the Plan to discontinue its contributions at any time and to terminate the Plan subject to the provisions of ERISA. In the event of Plan

termination, participants will become 100% vested in their accounts.

AZZ incorporated Employee Benefit Plan & Trust

Notes to Financial Statements (continued)

H. Income Tax Status

The Plan has received a determination letter from the IRS dated August 24, 1994, stating that the Plan is qualified under Section 401(a) of the Code, and, therefore, the related trust is exempt from taxation. Once qualified, the Plan is required to operate in conformity with the Code to maintain its qualification.

The Company, effective January 1, 2003, adopted the MFS Retirement Services, Inc. Non-Standardized 401(k) Profit Sharing Plan and Trust, which has received a favorable opinion letter from the IRS dated April 23, 2002 stating that the written form of the prototype plan is acceptable under Section 401(a) of the Code and that any employer adopting this prototype plan document will be considered to have a plan qualified under section 401(a) of the Code.

In March 2005, the Plan received a determination letter from the IRS stating that the Plan as adopted is qualified under Section 401(a) of the Code, and, therefore, the related trust is exempt from taxation.

Effective March 1, 2008, the Plan was amended to become a safe-harbor Qualified Automatic Contribution Arrangement ("QACA"), pursuant to Section 401(k)(13) of the Code, as added by the Pension Protection Act of 2006. As required by section 401(k) of the Code, the Plan provides that employees may not receive a distribution of their employer contributions while actively employed by AZZ, unless they have attained age 59½ or have experienced a financial hardship. Despite these restrictions, the Plan Administrator and Record-keeper inadvertently distributed elective deferral contributions and QACA matching contributions, inconsistent with the withdrawal restrictions applicable to such contributions under Section 401(k)(13)(D)(iii)(II) of the Code, to certain employees who requested in-service distributions from their Plan accounts.

The improper distributions occurred from October 2007 through June 2008 and relate to 74 Plan participants, with an aggregate amount of all the improper distributions of approximately \$199,700. This error was an operational failure and not a Plan document failure and, thus, is eligible for the self-correction program. AZZ attempted to contact affected participants for refund of the improperly distributed amounts; however no responses were received from the participants. In order to correct the distribution errors consistent with Revenue Procedure 2008-50, AZZ will make a contribution to the Plan during the 2010 Plan year in an amount equal to the gross amount of the improper distributions, plus earnings at a rate of 6% which will be placed in an unallocated suspense account and will properly report the distributions as taxable to the participants thereby making the Plan whole.

The Plan Administrator believes that with the correction of the operational issue in accordance with Internal Revenue Service guidance, the Plan is being operated in compliance with the applicable requirements of the Code and, therefore, believes that the Plan is qualified and the related trust is tax exempt.

AZZ incorporated Employee Benefit Plan & Trust

Notes to Financial Statements (continued)

I. Plan Amendments

Effective March 1, 2008, the Plan was amended to become a safe-harbor Qualified Automatic Contribution Arrangement ("QACA"), pursuant to Section 401(k)(13)of the Code, as added by the Pension Protection Act of 2006.

J. Reconciliation of Financial Statements to Form 5500

The following is a reconciliation of net assets available for benefits, at February 28, 2009 and February 29, 2008, per the financial statements to the Form 5500:

	2009	2008
Net assets available for benefits per the financial		
statements	\$ 29,752,050	\$ 31,934,439
Amounts allocated to withdrawing participants	-	(83,042)
Net assets available for benefits per the Form 5500	\$ 29,752,050	\$ 31,851,397

Amounts allocated to withdrawing participants are recorded on the Form 5500 for benefit claims that have been processed and approved for payment prior to the Plan's year end but not yet paid as of that date. For financial statement purposes benefit claims are not recorded until payment is made.

K. Subsequent Event

Effective August 1, 2009, the Company transferred the Plan assets from The Hartford to Mass Mutual and appointed Mass Mutual as trustee of the Plan.

AZZ incorporated Employee Benefit Plan and Trust

Form 5500, Schedule H, line 4i – Schedule of Assets (Held at End of Year)

February 28, 2009

Plan: 001

EIN: 75-0948250

				(e)
	(b)	(c)	(d)	Current
(a)	Identity of Issuer	Description of Investments	Cost	Value
*	MFS	MFS Total Return Fund A	**	\$ 4,336,966
*	MFS	MFS Value Fund A	**	2,755,489
*	MFS	MFS Bond Fund A	**	4,214,734
		Growth Fund of America		
	American Funds	R4	**	3,299,694
		MFS Global Equity Fund		
*	MFS	A	**	2,605,208
*	MFS	MFS Money Market Fund	**	3,611,292
	Columbia	Columbia Acorn Fund A	**	786,247
		AZZ incorporated common		
*	AZZ incorporated	stock	**	404,733
		Scudder Equity 500 Index		
	Scudder	Fund	**	502,792
		Interest rates ranging from		
*	Participant loans	3.25 to 9.25 percent	-0-	916,326
		_		
				\$ 23,433,481

^{*} Represents a party-in-interest to the Plan.

^{**} Cost omitted for participant directed investments.

SIGNATURES

The Plan. Pursuant to the requirements of the Securities Exchange Act of 1934, the persons who administer the AZZ incorporated Employee Benefit Plan & Trust (the "Plan") have duly caused this annual report for the Plan year ended February 28, 2009 to be signed on its behalf by the undersigned, thereunto duly authorized.

AZZ incorporated Employee Benefit Plan & Trust

Date: August 27, 2009 By /s/ DAVID H.

DINGUS

David H. Dingus

Administrative Committee Member

Date: August 27, 2009 By /s/ DANA L. PERRY

Dana L. Perry

Administrative Committee Member

EXHIBIT INDEX

Exhibit No. Description

23.1 Consent of Independent Registered Public

Accounting Firm